Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927952 | 0.92 | CNR2 (0.48) | CNR2CNR1KDM4EGAARET | |
| SCHEMBL6924555 | 0.89 | CNR2 (0.49) | CNR2CNR1PTPN11RET | |
| SCHEMBL6927528 | 0.84 | CNR2 (0.47) | CNR2CNR1RET | |
| SCHEMBL6926009 | 0.84 | CNR2 (0.50) | CNR2PTPN11KDM4ERET | |
| SCHEMBL6928035 | 0.83 | CNR2 (0.48) | CNR2PTPN11KDM4EGAARET | |
| SCHEMBL6923696 | 0.83 | RET (0.43) | CNR2MAPK1KDM4EGAARET | |
| SCHEMBL6925622 | 0.82 | HRH3 (0.45) | KDM4EGAARET | |
| SCHEMBL6928907 | 0.81 | CNR2 (0.46) | CNR2CNR1RET | |
| SCHEMBL6928854 | 0.81 | MGLL (0.44) | CNR2PTPN11KDM4EGAARET | |
| SCHEMBL6925946 | 0.79 | TDO2 (0.45) | KDM4EGAARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | CNR2 122/4885CNR1 118/4885PTPN11 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.